Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
sábado, octubre 03
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
ProQR Therapeutics NV
PRQR
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$1.64
0.005
0.31%
Últ. Act.: Oct 2, 5:39 PM
$1.61
-0.02
-1.23%
Get Report
Panorámica general
Noticias
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Propiedad
Comparar
Opciones
Informe de acciones
Privacy Manager
ProQR Therapeutics Financials
ProQR Therapeutics (PRQR) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
ProQR Therapeutics Q2 EPS $(0.09) Beats $(0.14) Estimate, Sales $10.183M Beat $5.560M Estimate
ProQR Therapeutics (NASDAQ:PRQR) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.14) by 35.71 percent. This is a 25 percent increase over losses of $(0.12) per share from
Benzinga Newsdesk
PRO
ProQR Therapeutics Q1 EPS $(0.15), Inline, Sales $2.381M Miss $5.530M Estimate
ProQR Therapeutics (NASDAQ:PRQR) reported quarterly losses of $(0.15) per share which met the analyst consensus estimate. This is a 50 percent decrease over losses of $(0.10) per share from the same period last year.
Benzinga Newsdesk
PRO
ProQR Therapeutics Q4 EPS $(0.09) Misses $(0.08) Estimate, Sales $5.458M Miss $8.550M Estimate
ProQR Therapeutics (NASDAQ:PRQR) reported quarterly losses of $(0.09) per share which missed the analyst consensus estimate of $(0.08) by 12.5 percent. This is a 10 percent increase over losses of $(0.10) per share from
Benzinga Newsdesk
PRO
ProQR Therapeutics Q3 EPS $(0.10), Inline, Sales $2.882M Miss $8.550M Estimate
ProQR Therapeutics (NASDAQ:PRQR) reported quarterly losses of $(0.10) per share which met the analyst consensus estimate. This is a 9.09 percent increase over losses of $(0.11) per share from the same period last year.
Benzinga Newsdesk
PRO
ProQR Therapeutics Q2 EPS $(0.12) Misses $(0.09) Estimate, Sales $4.327M Miss $4.408M Estimate
ProQR Therapeutics (NASDAQ:PRQR) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0.09) by 39.53 percent. This is a 300 percent decrease over losses of $(0.03) per share
Benzinga Newsdesk
PRO
ProQR Therapeutics Q2 EPS $(0.12) Misses $(0.09) Estimate
ProQR Therapeutics (NASDAQ:PRQR) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0.09) by 39.53 percent. This is a 300 percent decrease over losses of $(0.03) per share
Benzinga Newsdesk
